Abstracts tagged "methotrexate (MTX)"

Abstract Number: 1464 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)
Boulos Haraoui¹, J. Carter Thorne², Edward C. Keystone³, Melanie Poulin-Costello⁴, Eric Trottier⁵, Andrew Vieira⁶ and Janet E. Pope⁷, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Medical Communications, Amgen Canada, Mississauga, ON, Canada, ⁶Amgen Canada Inc., Mississauga, ON, Canada, ⁷St Joseph Health Care, London, ON, Canada
Background/Purpose: Data from the CAMEO study demonstrated that patients with rheumatoid arthritis (RA) who achieved low disease activity (LDA) after 6 months of combination therapy…
Abstract Number: 1475 • 2013 ACR/ARHP Annual Meeting
Subcutaneous Delivery Of Methotrexate Is Associated With Improved Treatment Survival Compared To Oral Administration For The Initial Treatment Of Patients With Early Rheumatoid Arthritis
Glen S. Hazlewood¹, J. Carter Thorne², Janet E. Pope³, Juan Xiong⁴, Gilles Boire⁵, Boulos Haraoui⁶, Carol A. Hitchon⁷, Edward C. Keystone⁸, Diane Tin⁹ and Vivian P. Bykerk¹⁰, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³St Joseph Health Care, London, ON, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁷Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁸Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: To determine the comparative survival of initial treatment with subcutaneous (sc) methotrexate (MTX) versus oral MTX for patients with early rheumatoid arthritis (ERA) in…
Abstract Number: 1437 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes At Two Years and The Effect Of Tocilizumab Discontinuation Following Sustained Remission In The Second Year Of The ACT-RAY Study
Thomas W.J. Huizinga¹, Philip G. Conaghan², Emilio Martin-Mola³, Georg Schett⁴, Howard Amital⁵, Ricardo M. Xavier⁶, Orrin Troum⁷, Maher Aassi⁸, Corrado Bernasconi⁹ and Maxime Dougados¹⁰, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B',, Sheba Medical Center,Tel-Hashomer, Tel-Aviv University, Tel-hashomer, Israel, ⁶Rheumatology Division, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁷University of Southern California School of Medicine, Santa Monica, CA, ⁸F. Hoffmann-La Roche, Basel, Switzerland, ⁹Consultant, Basel, Switzerland, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: 24- and 52- week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO])…
Abstract Number: 2767 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Combination Therapy and Monotherapy Versus Methotrexate In Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes From a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ariella Kelman⁶, Sophie Dimonaco⁷ and Nina Mitchell⁷, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Genentech, South San Francisco, CA, ⁷Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Recent recommendations support intensive treatment of patients (pts) with early rheumatoid arthritis (RA) to achieve remission or low disease activity.1-3 Tocilizumab (TCZ) was not…
Abstract Number: 1446 • 2013 ACR/ARHP Annual Meeting
The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate
T.W.J. Huizinga¹, Fiona Brock², Urs Kerkmann³ and Gaia Gallo³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Quanticate, Hitchin, Hertfordshire, United Kingdom, ³Pfizer Europe, Rome, Italy
Background/Purpose: Anti-TNF therapy in combination with a synthetic DMARD such as methotrexate (MTX) has been extensively shown to be superior to MTX and anti-TNF therapy…
Abstract Number: 2686 • 2013 ACR/ARHP Annual Meeting
Impact of Methotrexate Dose Reduction Upon Initiation of Adalimumab On Clinical and Ultrasonographic Parameters in Patients With Moderate to Severe Rheumatoid Arthritis
Gurjit S. Kaeley¹, Amy M. Evangelisto², Midori Jane Nishio³, Shufang Liu⁴ and Hartmut Kupper⁵, ¹College of Medicine, University of Florida, Jacksonville, FL, ²Arthritis, Rheumatic and Back Disease Associates, Voorhees, NJ, ³Diablo Clinical Research, Walnut Creek, CA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Methotrexate (MTX) is the recommended first-line disease-modifying antirheumatic drug (DMARD) for the treatment of moderately to severely active rheumatoid arthritis (RA). Whether patients (pts)…
Abstract Number: 1386 • 2013 ACR/ARHP Annual Meeting
Intracellular Concentration Of Methotrexate Is Influenced By Polymorphisms Of Gamma-Glutamyl Hydrolase Gene In Japanese Patients With Rheumatoid Arthritis
Tatsuhiro Yamamoto, Mai Kawazoe, Emiko Shindo, Natsuki Fujio, Kotaro Shikano, Kanako Kitahara, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Kaichi Kaneko, Natsuko Kusunoki, Yoshie Kusunoki, Kenji Takagi, Tomoko Hasunuma, Hirahito Endo and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is an anchor drug for treatment of rheumatoid arthritis (RA). Appropriate effective and/or tolerable doses of weekly pulse MTX therapy vary widely…
Abstract Number: 2369 • 2013 ACR/ARHP Annual Meeting
Long-Term Outcome Of Infliximab Therapy In Rheumatoid Arthritis Patients: Results From Japanese Multicenter Registry System
Nobunori Takahashi¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose: After demonstration of effectiveness of anti-tumor necrosis factor (TNF) agents in patients with rheumatoid arthritis (RA), their use has become common practice in treating…
Abstract Number: 1355 • 2013 ACR/ARHP Annual Meeting
Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of Methotrexate
Uwe Pichlmeier and Kay-Uwe Heuer, medac GmbH, Wedel, Germany
Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of RA, psoriasis, and psoriatic arthritis. Subcutaneously administered MTX is well absorbed and appears to overcome…
Abstract Number: 2341 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Adalimumab Plus Methotrexate Therapy In Rheumatoid Arthritis Non-Responders Receiving Methotrexate Monotherapy Or Adalimumab Combination Therapy: Results From The Optima Trial
Josef S. Smolen¹, Ronald F. van Vollenhoven², Roy Fleischmann³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita S. Rathmann⁶, Anabela Cardoso⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Leeds Teaching Hospital, Leeds, United Kingdom, ⁵AbbVie, Rungis, France, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie, Amadora, Portugal, ⁸AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁹University of California, San Diego, La Jolla, CA
Background/Purpose: EULAR recommendations advocate Methotrexate (MTX) as first line therapy. For patients (pts) who fail to attain remission or low disease activity (LDA) after 6…
Abstract Number: 1354 • 2013 ACR/ARHP Annual Meeting
Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Jaime Pachon¹, Alan Kivitz², Kay-Uwe Heuer³ and Uwe Pichlmeier³, ¹Arthritis and Rheumatic Care Center, Miami Research Associates, South Miami, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³medac GmbH, Wedel, Germany
Background/Purpose: Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to…
Abstract Number: 2321 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 24-Week Randomized Controlled Trial and Open-Label Extension Study
Josef S. Smolen¹, Ronald van Vollenhoven², Arthur Kavanaugh³, Vibeke Strand⁴, Jiri Vencovsky⁵, Michael H. Schiff⁶, Robert Landewé⁷, Boulos Haraoui⁸, Susan Walker⁹ and Désirée van der Heijde¹⁰, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, ⁴Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁵Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ⁸Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁹UCB Pharma, Raleigh, NC, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the RAPID2 randomized controlled trial (RCT; NCT00160602), certolizumab pegol (CZP) +MTX every 2 weeks (Q2W) improved signs and symptoms of rheumatoid arthritis (RA)…
Abstract Number: 1056 • 2013 ACR/ARHP Annual Meeting
Adherence To Methotrexate Therapy Among Patients With Rheumatoid Arthritis In Denmark: A Registry Based Cohort Study
Henning Bliddal¹, Robin Christensen², Mikkel Østergaard³, Tove Lorenzen⁴, Michael Sejer Hansen⁵, Peter Vestergaard⁶ and Stine A Eriksen⁶, ¹The Parker Institute, Copenhagen, Denmark, ²Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ³Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁴Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁵Gildhøj Privathospital, Copenhagen, Denmark, ⁶Medicine, Aalborg University, Aalborg, Denmark
Background/Purpose: Conflicting data have been presented on patient compliance with methotrexate (MTX) prescription. A Danish study found a mean period of 12.3% of the prescribed…
Abstract Number: 2229 • 2013 ACR/ARHP Annual Meeting
Alleviation Of Collagen-Induced Arthritis By Multifunctional Nanoparticle Containing Methotrexate
You-Jung Ha¹, Sun-Mi Lee², Ji-Hee Lim¹, Hyung-Joon Kim², Sang-Won Lee³, Soo Kon Lee⁴, Kyung-Hwa Yoo² and Yong-Beom Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Nanomedical Graduate Program, Department of Physics, Yonsei University, Seoul, South Korea, ³Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea, ⁴Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ⁵Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Methotrexate (MTX) is the most widely used disease-modifying anti-rheumatic drugs for the treatment of rheumatoid arthritis (RA). Despite of its efficacy, the continuous use…
Abstract Number: 748 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Methotrexate For Remission Induction and Maintenance In Granulomatosis With Polyangiitis In Routine Clinical Practice
Megan L. Krause¹, Misbah Baqir², Rodrigo Cartin-Ceba³, Tobias Peikert⁴, Karina Keogh⁴ and Ulrich Specks⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pulmonary/Critical Care, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Methotrexate has been shown to be effective for both induction (non-severe disease) and maintenance of remission in patients with Granulomatosis with Polyangiitis (GPA) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].